In addition, BRAF and MEK inhibitor combination therapy provided promising clinical results against melanoma brain metastases (48, 49) which have prompted assessing baseline clinical features associated with outcomes (45, 46, 48–51). The gene discussed is MAP2K7; the disease is melanoma.